Affimed (NASDAQ:AFMD) Share Price Crosses Below 50-Day Moving Average – What’s Next?

Affimed (NASDAQ:AFMD)’s stock price passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $1.39 and traded as low as $1.00. Affimed shares last traded at $1.04, with a volume of 78,367 shares trading hands.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on AFMD shares. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Affimed in a research report on Tuesday, December 10th. Wells Fargo & Company cut their price target on Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday, December 12th. Stifel Nicolaus lowered their price objective on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research note on Friday, November 15th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a research report on Tuesday, November 19th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $13.50.

Affimed Stock Down 1.0 %

The firm has a fifty day simple moving average of $1.39 and a 200 day simple moving average of $2.88. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Point72 Asset Management L.P. boosted its stake in Affimed by 4.6% during the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after buying an additional 15,108 shares in the last quarter. Intellectus Partners LLC lifted its holdings in shares of Affimed by 34.0% during the 4th quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 32,053 shares during the period. FMR LLC lifted its holdings in shares of Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,086 shares during the period. Finally, Jane Street Group LLC acquired a new stake in shares of Affimed during the 3rd quarter valued at about $44,000. 30.82% of the stock is currently owned by institutional investors and hedge funds.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.